Skip to main content
Clinical Trials/NL-OMON33598
NL-OMON33598CompletedNot Applicable

A PET study of dopamine function in healthy subjects with hallucinations - dopamine function in healthy subjects with hallucinations

niversitair Medisch Centrum Utrecht0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Physically healthy subjects, evaluated by medical history, physical examination and screening laboratory tests
  • Experiences hallucinations with a frequency of at least once a week.
  • Total SPQ score lower than 25
  • No diagnosis on axis I or II based on DSM -IV criteria, confirmed by the CASH and the SCID II interview.
  • Age between 18-60

Exclusion Criteria

  • Use of psychotropic medication within four weeks before the scanning
  • Drug or alcohol-abuse over a period of three weeks prior to the experiment. More then 15 cigarettes and more then 6 cups of caffeine containing coffee, cola or tea.
  • A history of neurological illness or other medical problems potentially having central nervous system sequellae.
  • Pregnancy, breast feeding and use of inadequate anti-conception.
  • Use of other medication potentially influencing cerebral blood flow.
  • Claustrophobia
  • Exposure to radioactivity leading to yearly cumulative dose of 10 mSv or more
  • Metal objects in or around the body (braces, pacemaker, metal fragments);
  • Exposure to radioactivity leading to a yearly cumulative dose of 10 mSv or more.

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Similar Trials

A PET study of dopamine function in... | Clinical Trial